Vascular endothelial growth factor and its receptors, including Flt-1 and Flk-1, are involved in angiogenesis under physiologic and pathologic conditions. Recently, Flt-1-expressing cells were reported to contribute to the intracranial growth of glioma cells. However, the role of Flt-1 signaling in solid tumor growth in s.c. tissue has not been elucidated. To investigate how Flt-1 signaling is involved in the proliferation of solid tumors, we implanted tumor cells into wild-type ( 
Introduction
Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR), including VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1), are essential for vasculogenesis and angiogenesis (1, 2) . VEGF-A, the most abundant VEGF and highly active in angiogenesis, binds Flt-1 and Flk-1. Even a heterozygous deficiency of the vegf-a gene resulted in the death of mice at embryonic days 7.5 to 8.5 (E7.5-8.5) due to a partial defect of blood vessels, suggesting that the concentration of VEGF-A in tissue is crucial for the normal development of vessels (3, 4) . VEGFRs belong to the Fms/kit/platelet-derived growth factor receptor (PDGFR) super gene family and are characterized by a cytoplasmic tyrosine kinase (TK) domain with kinase insert sequence (5) . The binding activity of Flt-1 for VEGF is 10-fold higher than that of Flk-1, whereas the TK activity of Flt-1 is one order of magnitude lower than that of Flk-1 (6, 7). Flt-1 binds VEGF-A, placenta growth factor (PlGF), and VEGF-B. Gene targeting studies have shown that flk-1 −/− mice die by E8.5 due to a lack of vasculogenesis and hematopoiesis (8) (9) (10) . On the other hand, flt-1 −/− mice die at E8.5 to E9.0 because of a disorganized system of blood vessels and an overgrowth of endothelial-like cells (11, 12) . Thus, flk-1 is regarded as a positive regulator for the proliferation of endothelial cell; in contrast, flt-1 is considered a negative regulator for angiogenesis in early development.
To investigate whether flt-1 TK itself is a negative signal transducer or not, we previously generated Flt-1 TK-deficient (Flt-1 TK −/− ) mice (13) . Although deficient in Flt-1 signaling, these mice have the ligand-binding domain of Flt-1 and exhibited normal development. The results indicate that the extracellular domain of Flt-1 is essential and sufficient to adjust endogenous VEGF levels during development. Moreover, we consider that the Flt-1 TK −/− mice are useful for investigating how the Flt-1 signal is important in pathologic angiogenesis (13, 14) . We and others have reported that Flt-1 is expressed not only on endothelial cells but also on monocyte/macrophages and, in some conditions, on smooth muscle cells and other cell types (15) (16) (17) . Flt-1 TK is involved in the survival signaling of liver sinusoidal endothelial cells and migration of monocyte/macrophages (18) .
Recent studies have shown the importance of cells expressing Flt-1 in the formation of premetastatic niches in tumor-bearing animals, reconstitution of BM tissues, expression of extracellular matrix metalloproteinase-9, and promotion of inflammatory diseases (19) (20) (21) (22) . Furthermore, Leek and colleagues and others reported that the number of macrophages infiltrated into tumors correlated with capillary density and a poor prognosis (23, 24) . However, the relationship between Flt-1 signaling and tumor progression in s.c. tissue has not been clarified.
Here, we show that, in solid tumor models, a deficiency of Flt-1 signal suppresses tumor angiogenesis, infiltration of macrophage lineage cells, and tumor growth. Furthermore, based on the results of bone marrow (BM) transplantation (BMT) experiments, we suggest that the Flt-1 signal on macrophage lineage cells derived from BM plays a major role in Flt-1-related tumor growth.
Materials and Methods

Cell lines and mice
A murine uterine cancer cell line HSML was kindly provided by Dr. Kudoh (Hirosaki University, Hirosaki, Japan). Lewis lung carcinoma cells (LLC) and a murine melanoma cell line B16 were purchased from the American Type Culture Collection. HSML cells were cultured in RPMI 1640 (Nacalai Tesque). LLC and B16 cells were maintained in DMEM (Nacalai Tesque). Each medium was supplemented with fetal bovine serum to 10%, and the cells were cultured at 37°C with 5% CO 2 .
All experiments using animal models were carried out according to guidelines, following a protocol approved by the ethics committees of the Animal Center of Institute of Medical Science in University of Tokyo and the Disease Model Research Center in Tokyo Medical and Dental University. Genotyping of all mice was performed as described previously (13) . Wild-type (Wt) C57BL/6 mice (6-8 weeks old; CLEA Japan, Inc.) were used as a control in this study and as BM recipients. Flt-1 TK −/− mice were used at the same age as Wt mice. Green fluorescent protein (GFP) mouse strain (RBRC00267) was provided by RIKEN BRC through the National Bio-Resource Project of the Japanese Government Ministry of Education, Culture, Sports, Science and Technology.
In vivo tumor growth experiments Eight-week-old mice were anesthetized and injected s.c. with 1 × 10 7 tumor cells. Tumors were measured every 2 days from day 7 for 3 to 4 weeks. After mice were euthanized, tumors were removed and either postfixed in 4% paraformaldehyde or directly embedded in optimal cutting temperature compound in a deep freezer at −80°C. Reverse transcription-PCR and real-time PCR Reverse transcription-PCR (RT-PCR) and real-time PCR were performed following a previous report (25) . Alternative splicing subtypes of mouse vegf-a were detected by RT-PCR with forward primer as 5′-ATGAACTTTCTGCTCTCTTG-GGTGC-3′ and reverse primer as 5′-TGGCTCACCGCCT-TGGCTTGTCAC-3′ (25) .
BMT
Immunohistochemistry
Fixed mouse tissues were cut 20-μm thick by Cryostat (Leica) and stained with the following antibodies: rat antimouse F4/80 (Serotec), rat anti-mouse platelet/endothelial cell adhesion molecule 1 (CD31; BD Bioscience), and rabbit anti-GFP (Invitrogen). Cryosections of fresh frozen mouse tissues were stained with rat anti-CD11b (BD Bioscience), hamster anti-CD31 (Millipore, MA), mouse anti-smooth muscle actin (SMA; Sigma), rabbit anti-PDGFRβ (eBioscience), and rat anti-NG2 (Millipore). Sections were incubated with appropriate secondary antibodies, with the nuclear staining dye To-Pro-3 (Invitrogen) and the In situ Cell Death Detection kit TMR red [terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL); Roche], and then analyzed with a confocal microscope (Radiance 2000, Bio-Rad).
Western blotting
Cell lysate was prepared with a lysis buffer containing 1% Triton-X 100 to solve cytosome. After centrifugation at 4°C to remove the supernatant, a one-fourth volume of 5× sample buffer containing 10% SDS for solving nucleus fraction was added to the precipitate. Aliquots were applied to the gel and transferred to a membrane, and then the membrane was incubated with rabbit anti-fibroblast growth factor-2 (FGF-2) antibody (Santa Cruz) or mouse anti-actin antibody (Millipore) as a primary antibody. Antirabbit IgG or antimouse IgG antibody was used as a secondary antibody, which was conjugated with alkaline phosphatase (Promega).
RNA interference experiment
Stealth RNA interference (RNAi; Invitrogen) for impairment of FGF-2 mRNA was transfected into LLC by Lipofectamine RNAi MAX (Invitrogen). Transfected cells were collected and implanted into s.c. tissue of Wt and Flt-1 TK −/− mice. An aliquot of cells was used to detect the levels of FGF-2 inhibition by real-time PCR. Tumor volume, degree of angiogenesis, and infiltration of macrophage lineage cells were examined.
Transfection of FGF-2 cDNA into B16 FGF-2 cDNA was transfected into B16 tumor cells by using pMX-puro containing mouse retroviral vector and Fugene 6 transfection reagent (Roche). After overnight infection, the culture medium was replaced to fresh medium containing 1.5 μg/mL puromycin. FGF-2-expressed clones were obtained after 1 to 2 weeks.
Statistical analysis
Results were expressed as the mean ± SEM. The means of two groups were compared using a two-tailed Student's t test. P < 0.05 was considered to be significant.
Results
Lack of Flt-1 signaling suppresses growth of solid tumors in mice
To elucidate whether Flt-1 signaling on the host side is involved in tumorigenesis in vivo, we used an allograft model and compared the tumor growth rates between Wt and Flt-1 TK −/− mice. HSML, B16, and LLC cells were inoculated s.c. 1D ). These results indicate that a lack of Flt-1 signaling significantly suppresses solid tumor growth and aggressiveness.
Angiogenesis was suppressed in tumor tissue in the
To clarify whether the suppression of tumor growth is due to a decrease in angiogenesis, we investigated the levels of angiogenesis in tumor tissue using immunohistochemical staining by CD31, a specific marker for endothelial cells. As a control, healthy skin tissue from Wt and Flt-1 TK −/− mice was stained with anti-CD31 antibody ( Supplementary  Fig. S1 ). No significant differences were observed in the non-tumor-bearing condition between Wt and Flt-1 TK −/− mice. However, numbers of CD31 + cells in tumor tissues were markedly reduced in Flt-1 TK −/− mice (Fig. 1B) .
The degree of angiogenesis was reduced to ∼39% for HSML, 40% for B16, and 67% for LLC in Flt-1 TK −/− mice (Fig. 1C) .
Interestingly, in the border area of tumors, including the dermis and muscle layer, CD31 + cell numbers were not significantly decreased in Flt-1 TK −/− mice. These results suggest that a lack of Flt-1 signal is involved in angiogenesis in the tumor but not in the border area.
A decrease in infiltration of macrophage lineage cells in tumor tissue correlates with reduced tumor progression Recent reports have indicated that the degree to which macrophages infiltrate tumor tissue is associated with prognosis and tumor angiogenesis in a variety of clinical conditions (23, 24) . We and others previously reported that Flt-1 is expressed not only on endothelial cells but also on monocyte/macrophages (15, 16) . Furthermore, we showed that migration activity to VEGF and PlGF and the expression of interleukin-6 (IL-6) and VEGF-A were decreased in peritoneal macrophages derived from Flt-1 TK −/− mice compared with those from Wt mice (13, 26 Fig. S1 ). The infiltration of macrophage lineage cells into HSML and B16 tumor tissues was strikingly suppressed in Flt-1 TK −/− mice. In contrast, numbers of macrophages in the border area of tumor tissues in Flt-1 TK −/− mice were similar to those in Wt mice ( Fig. 2A) . The infiltration of macrophages into tumors was 15% (HSML), 39% (B16), and 78% (LLC) in Wt mice (Fig. 2B) . These results suggest that the infiltration of macrophage lineage cells into some tumor tissues is at least partly dependent on Flt-1 signaling, although the border area of tumors is not affected. (Fig. 3) . These results indicate that SMA + and PDGFRβ + cells are also less numerous in tumors under Flt-1 TK-deficient conditions, although it is not clear whether the decrease is a direct effect of Flt-1 TK −/− or not.
FGF-2 was highly expressed in LLC cells compared with other tumor cells and contributed to tumor progression
Because LLC cell growth in Flt-1 TK −/− mice was similar to that in Wt mice, the question arises whether this refractory feature of Flt-1 signaling is due to high levels of other angiogenic factors different from the VEGF-VEGFR system. Realtime PCR was performed to assess the expression patterns of angiogenic factors and chemoattractants at the mRNA level in vitro (Fig. 4A) . LLC cells expressed FGF-2, a major angiogenic factor, at levels of two orders of magnitude higher than that in HSML and B16 cells. By Western blotting, FGF-2 protein was detected in LLC cell lysate but was undetectable in the conditioned medium (Fig. 4B) . The FGF-2 expressed in LLC cells had a molecular weight of 24 kDa, the largest of the four subtypes (18, 21, 22.5, and 24 kDa). Expression of VEGF-A in LLC was not significantly different from that in HSML and B16 (Fig. 4A) . Alternative splicing subtypes of VEGF-A detected by RT-PCR was also similar among these three tumors (Fig. 4C) .
To clarify the role of FGF-2 in LLC tumor growth, we used small interfering RNA (siRNA) method to silence the gene (Fig. 5A ). When we used two independent siRNAs efficiently suppressing FGF-2 mRNA, interestingly, the LLC with FGF-2 silencing but not the control LLC with scrambled siRNA showed slower tumor growth in Wt mice (Fig. 5B) . Furthermore, the growth rate of the LLC with FGF-2 silencing in Flt-1 TK −/− mice was significantly slower than that in Wt mice.
These results indicate that FGF-2 contributes to LLC tumor growth in vivo, and FGF-2 expression in LLC is a factor to mask the different tumor growth rates between Wt and Flt-1 TK −/− mice.
To further examine the role of FGF-2, we introduced FGF-2 cDNA into B16 cells, which express very low levels of FGF-2. Expression of FGF-2 in B16 was confirmed by Western blotting (Fig. 5C) . The B16 transfected with control vector showed tumor growth slower in Flt-1 TK −/− mice than in Wt mice. However, the tumor growth rate of FGF-2-expressing B16 in Flt-1 TK −/− mice was similar to that in Wt mice (Fig. 5D ). These results further support the above suggestion that FGF-2 expression modifies tumor growth rate in Wt and Flt-1 TK −/− mice and masks a difference. In both RNAi and transfection of FGF-2 experiment, FGF-2 had a minor effect on angiogenesis and infiltration of macrophage lineage cells (Supplementary Fig. S2 ). Blood vessels in HSML and B16 tumors in BMT mice were examined by immunohistochemical staining. Tumor angiogenesis was significantly suppressed in Wt/Flt-1 TK −/− mice compared with that in Wt/Wt mice (Fig. 6B, a-d) . The infiltration of macrophage lineage cells detected by F4/80 staining was also dramatically decreased in the tumor tissue of Wt/Flt-1 TK −/− mice (Fig. 6B, e-h ). However, angiogenesis and the infiltration of macrophage lineage cells in the border area of tumors were not significantly different between Wt/Wt and Wt/Flt-1 TK −/− mice (Fig. 6C) .
To evaluate whether the reduction of macrophage lineage cell infiltration in Flt-1 TK −/− condition is due to a decrease in survival of these cells or not, we checked the apoptotic cells in tumor tissue with TUNEL staining in BM-transplanted mice. In HSML tumor tissue, GFP + myeloid cells were nonapoptotic ( Supplementary Fig. S4 ). B16 tumor contained some apoptotic sites, but apoptotic myeloid cells (GFP + and TUNEL + double-positive cell) were not detected. Thus, it suggests that Flt-1 signal is used for infiltration but not for survival of macrophage lineage cells; however, we cannot rule out the possibility that Flt-1 signal is used for retention of cells in tumor tissue.
These results indicate that Flt-1 signaling on BM-derived cells such as macrophages is important for tumor angiogenesis and tumor growth in HSML and B16 cells.
Discussion
In this study, we have shown that the s.c. growth of HSML uterine tumors and B16 melanomas, but not Lewis lung carcinomas, is significantly dependent on Flt-1 signaling. Also, we showed that in Flt-1 signaling-deficient mice, slower tumor growth was associated with less tumor angiogenesis and less infiltration of monocyte/macrophage lineage cells into tumor tissue. Furthermore, by BMT, we found that Flt-1 signaling in BM-derived cells, most likely in macrophage lineage cells, is important for rapid tumor growth and aggressiveness; thus, the Flt-1 kinase itself and its downstream signaling are attractive targets for suppression of primary tumor growth and metastasis in cancer patients.
In mammals, Flt-1 protein is highly expressed in vascular endothelial cells and monocyte/macrophages. Under hypoxic conditions, smooth muscle cells were also reported to express Flt-1 in vitro. The question is which of these Flt-1-expressing cells are important for the promotion of tumor growth. Although PlGF, a Flt-1-specific ligand, promotes the survival of endothelial cells in vitro (6, 33) , transplantation experiments using Flt-1 TK −/− BM cells clearly indicated that tumor growth was slower in Wt/Flt-1 TK −/− mice than in Wt/Wt mice (Fig. 6) . Meanwhile, Flt-1 signal does not affect the apoptosis of myeloid cell in this model by TUNEL assay ( Supplementary Fig. S4 ). Therefore, the regulation of tumor growth through Flt-1 signaling is related at least partly to BM-derived cells such as macrophages but much less so to vascular endothelial cells. We reported that VEGF-dependent and PlGF-dependent migration activities were significantly decreased in the peritoneal macrophages derived from Flt-1 TK −/− mice compared with those from Wt mice. In addition, we showed a remarkable reduction of mRNAs for IL-6 and VEGF in peritoneal macrophages obtained from Flt-1 TK −/− mice (13, 26) . Furthermore, Kerber and colleagues (34) examined migration activity of monocytes isolated from the venous blood of Flt-1 TK −/− mice and showed that the activity toward VEGF and PlGF was significantly suppressed. These experiments strongly suggest that a lack of Flt-1 signaling attenuates infiltration of macrophages into tumor tissue via VEGF or PlGF, which is secreted from tumor cells and other cells in tumor microenvironment, and that tumor angiogenesis stimulated by tumor-infiltrated macrophages is decreased in Flt-1 TK −/− mice.
Tumor progression of LLC even in Flt-1 TK −/− mice Although the growth of HSML and B16 tumors was highly dependent on Flt-1 signaling, the growth rate of LLC was similar between Wt and Flt-1 TK −/− mice.
We hypothesized that another angiogenic factor(s) is expressed in LLC and overcomes the deficiency of Flt-1 signal in host cells. The mRNA levels of VEGF-A were not significantly different among HSML, B16, and LLC, and the expression patterns of VEGF-A subtypes were also similar to these cells (Fig. 4C) . We found that FGF-2 mRNA levels were >10-fold higher in LLC cells than in HSML and B16 cells (Fig. 4A) . Recently, FGF-2 has been reported to play an important role in the resistance of tumors to anti-VEGF-VEGFR therapy in mice (35) .
To examine the role of FGF-2 in LLC tumor progression, we suppressed FGF-2 expression with RNA silencing method. Interestingly, the LLC with FGF-2 silencing showed slower tumor growth in the Wt mice. Furthermore, growth rate of the LLC with FGF-2 silencing in Flt-1 TK −/− mice were significantly slower than that in the Wt mice (Fig. 5B) . In another experiment, B16 cells transfected with FGF-2 cDNA mimicked the phenotype of original LLC (Fig. 5D ). These results indicate that (a) FGF-2 contributes to LLC-tumor growth in vivo and (b) FGF-2 expression in LLC is a factor to mask the different tumor growth rates between Wt and Flt-1 TK −/− mice.
Another question is which form(s) of FGF-2 in LLC, secreted form or intracellular form, is important for these phenotypes. In the literature, several groups already showed that 24-kDa intracellular-type FGF-2 localizes in the nuclei and promotes cell proliferation (36) (37) (38) (39) . We found that FGF-2 expressed in LLC is mostly the intracellular type (Fig. 4B) , which might directly stimulate cell proliferation. A secreted type of FGF-2 seems a minor population in LLC.
Flt-1 could be an attractive target for suppression of tumor growth
Lutten and colleagues recently published that the MF1 antimouse Flt-1 neutralizing antibody from ImClone has a clear tumor-suppressing effect, although antimouse VEGFR-2 neutralizing antibody DC101 had a better effect (40) . In addition, several reports described that antihuman Flt-1 neutralizing antibodies had a cancer-suppressive effect when Flt-1-expressing human lymphoma or breast cancer cells were inoculated in immunodeficient mice (41) (42) (43) (44) . Because Flt-1 has a 10-fold higher affinity to VEGF compared with VEGFR-2, a higher concentration of antiFlt-1 antibody may be required to obtain a better tumorsuppressive effect. Furthermore, some neutralizing antibodies to Flt-1 compete with the VEGF and release it from Flt-1. In this case, VEGF released from Flt-1 might bind and activate VEGFR-2. Thus, it seems to be important to develop Flt-1 blocking antibody with better quality such as noncompetitive type.
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